Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., and Novartis Pharmaceuticals Corporation.
2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care
Although the advent and proliferation of precision medicine and paradigm-shifting methods of solid tumor assessment are revolutionizing how we diagnose and stratify risk among patients with cancer, successful implementation of these platforms has still mostly been limited to the academic setting, with slow dissemination to community practices. Appropriate use of established and emerging testing options for cancers commonly encountered by busy clinicians like you requires an in-depth understanding of the technology, paired with a coordinated effort by the multidisciplinary healthcare team. The 2nd Annual Precision Medicine Through Plasma: Using Liquid Biopsies in Contemporary Oncology Care is being launched to address the rapidly evolving science and associated therapeutic developments resulting from the emergence of novel testing strategies such as liquid biopsies.
It is imperative for you and your healthcare professionals to not only be aware of the various actionable mutations, but also methods to identify these mutations, when these tests should be ordered, and how to interpret the results of these tests to inform treatment decisions. Awareness of these advances and the ability to apply this knowledge have the potential to bring new treatment strategies into play that best leverage biomarkers and individualized therapy, maximizing outcomes for your patients across multiple cancer subtypes, and providing better patient care at each point along the disease continuum.
This live CME workshop will provide you with the opportunity to increase your confidence and competence in selecting emerging novel testing strategies such as liquid biopsies and plasma testing as you strive to provide the best care for your patients. Key experts in lung, breast, and gastrointestinal malignancies will provide an overview of the latest clinical data on liquid biopsies, followed by detailed, real-world, and practical case-based discussions among a multidisciplinary faculty. Ample question-and-answer time will also be provided for attendees to interact directly with the expert faculty.
Benefits of Attending
- Understand the role of testing, sequencing, and genomics
- Evaluate the utility of available plasma-based tests
- Get the experts’ perspectives on this advancing technology
Acknowledgment of Commercial SupportThis activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., and Novartis Pharmaceuticals Corporation.
This educational activity is intended for medical oncologists, pathologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.
Upon completion of this activity, participants should be better prepared to:
- Compare the relative strengths and limitations of liquid biopsy against those of conventional tissue biopsy
- Identify the scientific foundations of liquid biopsy technology
- Contrast available and emerging testing technologies with respect to sensitivity, specificity, and clinical applications for patients with cancer
- Appraise clinical evidence pertaining to specific testing modalities that may help to individualize treatment protocols for patients with cancer
What You'll Learn
- The importance of testing, sequencing, and advanced genomics for your patients
- Differences regarding diverse types of testing – including the appropriate clinical utility of liquid biopsy
- Potential application in the clinic – from diagnosis through treatment to management in various tumor settings
Program Chair:Benjamin P. Levy, MD
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
You must be logged in to PER to register for this meeting
Or Register for PER now